Project Grant K99CA297133
- Federal Grant Award Summary The National Cancer Institute awarded the University of Chicago a $185,760 Project Grant under the Cancer Research Manpower program (CFDA 93.398) on September 15, 2025, with a completion date of August 31, 2028. The award supports a research project titled "Targeting Glycerol Metabolism in Anti-Tumor Immunity," which investigates the mechanistic relationship between obesity-related metabolic changes and cancer progression, with particular focus on how...
- Federal Project Grant Award Summary The University of Chicago received a $518,151 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) effective July 1, 2026, through June 30, 2031. The award supports research to advance Nicotinamide N-Methyltransferase (NNMT) inhibitor development and investigate mechanisms by which NNMT inhibition can sensitize immunotherapy-resistant tumors to immune checkpoint inhibitors. The research focuses on the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Chicago a project grant of $169,204.94 under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2025. This funding supports research investigating how the dietary nutrient zeaxanthin enhances anti-tumor immunity by reprogramming CD8+ T cell function. The research deliverables include preclinical studies demonstrating zeaxanthin's translational potential across multiple...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $588,289 Project Grant to the University of Chicago under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year award funds research focused on mechanistically characterizing how BH3 (Bcl-2 homology domain 3) mimetic therapeutics alter T cell function through BCL-2 (B-cell lymphoma-2) family protein interactions. The research aims to advance understanding of...
- Federal Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded the University of Illinois a $412,249 Project Grant effective June 5, 2026, through May 31, 2028, to develop precision liver cancer modeling through CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) editing of primary human hepatocytes. The research addresses critical limitations in current hepatocellular carcinoma (HCC) models by creating a versatile platform that...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Illinois a $386,279 Project Grant on July 10, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop innovative immunotherapy screening capabilities. The grant funds the creation of a microfluidic device cassette and associated functional immune assay protocols designed to enable personalized immunotherapy screening directly on core needle biopsies from cancer patients. This...
- Federal Project Grant Award Summary The University of Chicago received a $372,628 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 12, 2025, with completion targeted for August 31, 2028. This award supports research into spatiomolecular profiling of human cancer at scale, specifically focused on developing and advancing spatially resolved transcriptomics (ST) technologies for analyzing tumor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $663,340 Project Grant to the University of California, Berkeley under the Cancer Biology Research program (CFDA 93.396) to conduct fundamental research on regulatory T cell-mediated suppression of tumor elimination. The award, made on August 27, 2025 with completion targeted for July 31, 2030, will fund investigations into how the local ablation of intra-tumoral regulatory T cells (IT-Tregs) mobilizes natural killer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Illinois a $412,249 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 13, 2026, for research focused on identifying novel innate immune checkpoint receptors that regulate phagocytosis in cancer and transplantation contexts. The project, scheduled for completion by April 30, 2027, will deliver research products addressing two specific aims: (1) identification and validation of...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
The National Cancer Institute awarded the University of Chicago a Project Grant of $129,285 under the Cancer Research Manpower program (CFDA 93.398) on June 4, 2026, with completion targeted for May 31, 2028. This research initiative focuses on integrated fatty acid profiling to establish linkages between body mass index (BMI) and the efficacy of anti-tumor immunotherapy. The project systematically analyzes circulating free fatty acids (FFAs) in melanoma patients to identify immunomodulatory compounds that enhance immune checkpoint inhibitor (ICI) efficacy. The research employs a dual-track approach: comparative analysis of FFA levels in patient serum samples and screening of a curated library of 62 commercially available FFAs to identify those enhancing immune cell functions. The deliverables include mechanistic insights into how essential fatty acids (EFAs) regulate CD8+ T cells through G-protein coupled receptors (GPCRs), with particular emphasis on differentiating immunoenhancing fatty acids (arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid) from immunoinhibitory variants. In vivo studies demonstrating the effects of oral FFA administration on anti-tumor immunity and tumor growth progression contribute to the research output. These findings are intended to support the development of novel immunotherapy enhancement strategies and advance the National Cancer Program's strategic priorities in cancer research and treatment innovation.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $129.3k | 6/8/26 |